This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Reduced Leaflet Motion After Transcatheter Aortic Valve Replacement
Puzzling subgroup from the GALILEO trial, which appears in the same issue of the periodical as an article that discredits the use of rivaroxaban as thromboprevention strategy :
And yet, in this particular subgroup, a subclinical benefit on leaflet mobility is being suggested! It would appear that the GALILEO will be discussed at length and in detail in the months and years to come.